Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 3/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.52 |
| ▸ | PDE4A | P27815 | 5/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.52 |
| ▸ | PYGL | P06737 | 1/20 | 0.45 |
| ▸ | PDE1A | P54750 | 1/20 | 0.44 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.44 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL257366 | 0.90 | KAT2B (0.53) | PDE5APDE4DPDE4BPDE4APDE4C | |
| SCHEMBL10046969 | 0.88 | PDE5A (0.44) | PDE5APDE4DPDE4BPDE4APDE4C | |
| SCHEMBL257358 | 0.87 | PDE4D (0.48) | PDE5APDE4DPDE4BPDE4APDE4C | |
| SCHEMBL15197136 | 0.85 | PDE4D (0.48) | PDE5APDE4DPDE4BPDE4APDE4C | |
| SCHEMBL10047114 | 0.79 | ALDH1A1 (0.47) | PYGLKMT2AALDH1A1POLB | |
| SCHEMBL10047113 | 0.78 | KMT2A (0.51) | PYGLKMT2AALDH1A1POLB | |
| SCHEMBL10047545 | 0.78 | ALDH1A1 (0.55) | PYGLKMT2AALDH1A1POLB | |
| SCHEMBL257369 | 0.77 | KAT2B (0.50) | PDE5APDE4DPDE4BPDE4APDE4C | |
| SCHEMBL257243 | 0.77 | ALDH1A1 (0.48) | PDE4DPYGLKMT2AALDH1A1POLB | |
| SCHEMBL257352 | 0.76 | LMNA (0.54) | PDE4DPDE4APYGLKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895552-B2 | Cyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20130217692-A1 | CYCLIC AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| EP-2612848-A1 | CYCLIC AMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012029942-A1 | CYCLIC AMIDE DERIVATIVE | 大日本住友製薬株式会社 (JP) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217692-A1 | CYCLIC AMIDE DERIVATIVE | HDAC10, H1-10, H1-0 | PDE5A 2741/4885PDE4D 2496/4885PDE4B 1579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.